Journal of Neurology, Neurosurgery & Psychiatry | VOL. 89
Read

040 An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis

Publication Date May 24, 2018

Abstract

IntroductionAn independent meta-analysis; Pakpoor et al. Neurol Neuroimmunol Neuroinflamm 2015;2:e158) in Phase III trials (with a 2 year duration) of disease modifying drugs (DMDs) in patients with relapsing multiple sclerosis found no increased rate of malignancy with cladribine tablets (CT) versus other DMD treatments. Data from additional trials involving CT 3.5 mg/kg (CT3.5) and a safety registry (up to 8 years’ follow-up) allow further insights into malignancy risk. Objective is to assess malignancy risk with CT3.5 monotherapy and placebo (PBO) in data from 3 Phase III trials and a registry, and compare the incidence rate with a global database.MethodsThe CT 3.5 population comprised 923 patients (3433 patient-years’ [PY] total exposure time) and the PBO group comprised 641 patients (2026 PY). Individual case reports of malignancies were reviewed by independent, blinded adjudication committee. Standardised incidence ratios (SIR) were calculated using the GLOBOCAN reference population (excluding non-melanoma skin cancers [NMSCs]) and a Danish reference population for NMSC rates.ResultsThe incidence per 100 PY of confirmed malignancy was CT3.5 0.293 (95%CI 0.158–0.544) and PBO 0.148 (95%CI 0.048–0.460); the risk difference 95% CI included 0 (−0.166–0.414). The CT 3.5 malignancy SIR was almost identical (0.97, 95% CI 0.44–1.85) to the GLOBOCAN matched reference population. The PBO group SIR was numerically lower (0.48, 95% CI 0.14–1.53). There were no cases of haematological, lymphoproliferative or virus-induced cancers. T...

Concepts
Powered ByUnsilo

Cladribine Tablets
Standardised Incidence Ratios
Cladribine Tablets In Patients
Incidence Of Malignancies
Disease Modifying Drugs
Matched Reference Population
Incidence Of Skin Cancer
Tablets In Patients
Reference Population
Placebo

Introducing Weekly Round-ups!Beta

Powered by R DiscoveryR Discovery

Round-ups are the summaries of handpicked papers around trending topics published every week. These would enable you to scan through a collection of papers and decide if the paper is relevant to you before actually investing time into reading it.

Climate change Research Articles published between Jun 13, 2022 to Jun 19, 2022

R DiscoveryJun 20, 2022
R DiscoveryArticles Included:  5

Understanding the effects of the snow ratio on glacier mass balance under variable climatic conditions is crucial for predicting how glaciers will res...

Read More

Good health Research Articles published between Jun 13, 2022 to Jun 19, 2022

R DiscoveryJun 20, 2022
R DiscoveryArticles Included:  5

In West Africa, the various types of diabetes according to WHO or the American Diabetes Association (ADA) are endemic; a particular type referred to a...

Read More

Gender Equality Research Articles published between Jun 13, 2022 to Jun 19, 2022

R DiscoveryJun 20, 2022
R DiscoveryArticles Included:  5

This study aims to evaluate changes in the presence of women on Spanish boards after the Unified Good Governance Code of Listed Companies (2006) and t...

Read More

Coronavirus Pandemic

You can also read COVID related content on R COVID-19

R ProductsCOVID-19

ONE PROBLEM . ONE PURPOSE . ONE PLACE

Creating the world’s largest AI-driven & human-curated collection of research, news, expert recommendations and educational resources on COVID-19

COVID-19 Dashboard